Clinical Trial Details

Trial ID: L0218
Source ID: NCT04321343
Associated Drug: PXL065
Title: Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
Acronym: --
Status: Active, not recruiting
Study Results: No Results Available
Results: --
Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Drug: PXL065|Drug: Placebo oral tablet
Outcome Measures: Change in the percentage of liver fat content (assessed by MRI-PDFF)|Assessment of the safety and tolerability|Liver biospy|Changes in biological parameters
Sponsor/Collaborators: Poxel SA
Gender: All
Age: 18 Years to 75 Years ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 123
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Start Date: September 1, 2020
Completion Date: June 2022
Results First Posted: --
Last Update Posted: December 7, 2021
Locations: Study site 11, Chandler, Arizona, United States|Study site 12, Glendale, Arizona, United States|Study site 13, Tucson, Arizona, United States|Study site 21, Tucson, Arizona, United States|Study site 17, Chula Vista, California, United States|Study site 16, Fresno, California, United States|Study site 04, Huntington Park, California, United States|Study site 05, Los Angeles, California, United States|Study site 22, Orange, California, United States|Study site 06, Panorama City, California, United States|Study site 07, Santa Ana, California, United States|Study site 15, Boca Raton, Florida, United States|Study site 31, Fort Myers, Florida, United States|Study site 08, Port Orange, Florida, United States|Study site 01, Sarasota, Florida, United States|Study site 28, West Des Moines, Iowa, United States|Study site 18, Kansas City, Kansas, United States|Study site 24, Flowood, Mississippi, United States|Study site 10, Jackson, Mississippi, United States|Study site 27, East Syracuse, New York, United States|Study site 14, Fayetteville, North Carolina, United States|Study site 29, Summerville, South Carolina, United States|Study site 25, Chattanooga, Tennessee, United States|Study site 30, Clarksville, Tennessee, United States|Study Site 02, Germantown, Tennessee, United States|Study site 19, Austin, Texas, United States|Study site 09, Edinburg, Texas, United States|Study site 23, Edinburg, Texas, United States|Pinnacle Clinical Research (Study site 20), San Antonio, Texas, United States
URL: https://ClinicalTrials.gov/show/NCT04321343

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D291 PXL065 Chemical drug -- AMPK activator Improve insulin resistance Under clinical trials Details